<DOC>
	<DOCNO>NCT00210353</DOCNO>
	<brief_summary>Assess therapeutic activity safety combination Chlorambucil Rituximab MALT lymphoma determine whether addition Rituximab Chlorambucil improve outcome MALT lymphoma comparison treatment Chlorambucil alone . In April 2006 , third arm treatment add compare antitumor activity safety rituximab alone vs chlorambucil alone</brief_summary>
	<brief_title>Randomized Trial Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab MALT Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>1. histologically proven diagnosis CD20positive marginal zone Bcell lymphoma MALT type arisen extranodal site 2. stage ( Ann Arbor IIV ) 3. either de novo , relapse disease follow local therapy ( include surgery , radiotherapy antibiotic H. pyloripositive gastric lymphoma ) 4. evidence histologic transformation high grade lymphoma 5. measurable evaluable disease 6. age &gt; 18 7. life expectancy least 1 year 8 . ECOG performance status 02 9. prior diagnosis neoplasm within 5 year , except cervical intraepithelial neoplasia type 1 ( CIN1 ) localize nonmelanomatous skin cancer 10. prior chemotherapy 11. prior immunotherapy antiCD20 monoclonal antibody 12. prior radiotherapy last 6 week 13. corticosteroid last 28 day , unless prednisone chronically administer dose &lt; 20 mg/day indication lymphoma lymphomarelated symptom 14. evidence clinically significant cardiac disease , define history symptomatic ventricular arrhythmia , congestive heart failure myocardial infarction within 12 month study entry 15. evidence symptomatic central nervous system ( CNS ) disease 16. impairment bone marrow function ( WBC &gt; 3.0x109/L , ANC &gt; 1.5x109/L , PLT &gt; 100x109/L ) , unless due lymphoma involvement 17. major impairment renal function ( serum creatinine &lt; 1,5x upper normal ) liver function ( ASAT/ALAT &lt; 2,5 upper normal , total bilirubin &lt; 2,5x upper normal ) , unless due lymphoma involvement 18. evidence active opportunistic infection 19. know HIV infection 20. active HBV and/or HCV infection 21. pregnant lactate status 22. appropriate contraceptive method woman childbearing potential men 23. absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial 24. informed consent must give accord national/local regulation randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>